What Can You Expect at the Premier Pulmonary Fibrosis Forum in 2025?
The 9th IPF Summit offers a deep dive into the next generation of therapeutic development. With the efficacy benchmarks previously set now over a decade old, and new readouts on the horizon, the field is primed for disruption. This year’s gathering of experts will explore the data, endpoints, biomarkers, and trial designs shaping clinical success today. We’ll tackle big questions including: What does disease modification really look like? Can we safely target TGFB? Are we finally ready to reverse fibrosis rather than just slow it down? Expect sessions featuring physician perspectives on treatment selection, strategies to demonstrate value and efficacy in a changing landscape, and fresh approaches in RNA therapies, antifibrotics, and regenerative medicine.
Unmissable Event Highlights for 2025
From Setbacks to Solutions: Translating Clinical Misses into Therapeutic Wins
From Galecto to FibroGen to Pliant, recent high-profile Phase 2 and 3 trial failures in IPF have laid bare the complexity of this disease and the critical gaps still hampering progress. In this deep-dive session, clinical leaders and translational experts will dissect trial designs, targets, patient populations, and biomarker strategies to draw out hard-won insights and lay a smarter, data-informed path forward.
With Expert Insights From:
- Cara Williams, Vice President, Head of Preclinical Biology: Inflammation & Immunology, Pfizer
- Paul Ford, Independent Consultant, Former Chief Medical Officer of Galecto & Former Vice President & Therapeutic Area Head Respiratory Medicine, Galapagos
- Toby Maher, Professor of Clinical Medicine and Director of Interstitial Lung Disease, University of Southern California
Understanding & Adapting to a Changing Pulmonary Landscape
With new modalities on the rise and nerandomilast’s success setting a fresh clinical benchmark, the treatment paradigm for IPF is shifting. This group of frontline physicians, and industry decision-makers will examine the evolving standard of care, physician priorities, and how to position new candidates in an increasingly competitive landscape.
With Expert Insights From:
- Susanne Stowasser, Associate Head of Medicine, TA Inflammation, Boehringer Ingelheim
- Bertil Lindmark, Chief Medical Officer, Vicore Pharma Holding
- Eric White, Senior Clinical Program Lead, ILD, Boehringer Ingelheim
- Carol Ann Satler, Vice President Clinical Development, Insilico Medicine
Maximizing Preclinical Packages to Enhance Translational Confidence
Designing a robust preclinical package is more crucial than ever to avoid clinical setbacks. This session explores what high-confidence candidate nomination looks like today, with a focus on modeling functional outcomes, selecting translatable biomarkers, integrating lung organoid and fibrotic tissue systems, and demonstrating meaningful PoC across modalities.
With Expert Insights From:
- Matthew Thomas, Department Head, Immunology & Respiratory, Boehringer Ingelheim
- Billy Fahy, Executive Director, Early Clinical Lead, Clinical Research & Early Programs, Respiratory, GSK
Rethinking IPF Drug Development: Target Discovery in the Next Era
As TGFB, falls short again, what truly makes a viable IPF target in 2025? This discussion explores what it means to “rethink” target discovery, from revisiting known biology through new lens (multi-omics, single-cell data) to harnessing AI and spatial mapping to guide novel target selection.
With Expert Insights From:
- Cara Williams, Vice President, Head of Preclinical Biology: Inflammation & Immunology, Pfizer
- Dori Thomas-Karay, Founder & Chief Executive Officer, Synthis Therapeutics
- Min Lu, Executive Director, Biology, Eli Lilly and Company
Repairing the Fibrotic Lung: Translating Regenerative Approaches into Clinical Reality
With more targets being explored, the field is turning toward regeneration to not only slow decline but restore lung architecture and function. This forward-looking session brings together regenerative medicine pioneers and translational leaders to explore the promise and current limitations of stem cell therapies, epithelial restoration, and airway remodeling. Key topics include biomarker development, imaging challenges, and how to define meaningful clinical endpoints for regeneration in IPF.
With Expert Insights From:
- Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics
- Lorna Harries, Chief Scientific Officer & Co-founder, SENISCA and Professor of Molecular Genetics, University of Exeter
- Ahmed Mousa, Chief Executive Officer, Vicore Pharma
- Marco Quarta, Co-Founder and Chief Scientific Officer, Rubedo Life Sciences
Divide & Conquer
The progressive pulmonary fibrosis field is diverse with different stakeholders laced across different stages of development, which is why we have meticulously researched with subject matter experts across all stages to identify the key challenges the community is facing.
On top of this years expert plenary sessions, by splitting into 2 dedicated tracks (Emerging Biology & Early Translation and Late Translation & Clinical), our speakers have tailored their presentations to dive into specific challenges for those stages of development providing even more relevant content for you.
By sending different members of the team across the drug pipeline, you can be sure you’ve left no stone unturned and fully prepare your team to capitalize on the new found pathway to success.
Explore the Full Event Guide
- 35+ Expert Speakers
- 3 Days of Unmissable Data-Driven Content
- Brand-New Probing Seminar Afternoon
- 4 Deep Dive Discussion-Based Workshops
- All at the Only Industry-Based Drug Development Summit
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive regulatory insights during our packed agenda, interactive roundtables, and new CXOs’ panel discussion.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.